Managing Unresectable Hepatocellular Carcinoma: Focus on Systemic Therapies
This activity contains:
- CME/CNE-Certified Live Grand Rounds and Webinars
- Downloadable Slide Deck (a non-certified educational resource)
The goal of this activity is provide updated information on the efficacy and safety of approved and investigational therapies for unresectable HCC, discuss the importance of multidisciplinary and interprofessional collaboration in managing this condition, and present useful tips on using a shared decision-making approach to management of HCC.
Advances in the understanding of the molecular pathogenesis of hepatocellular carcinoma (HCC) have broadened the potential for effective molecular targeted therapies. However, the management of unresectable HCC continues to be challenging. It is important that healthcare providers involved in the management of HCC have a good understanding of the current therapeutic options and that they stay up-to-date regarding the emerging therapies for unresectable disease. However, in light of the complexity of treatment and the rapid pace of treatment-related developments, this can be a difficult goal to achieve and maintain.
This activity will provide updates on approved and investigational therapies for unresectable HCC, discuss the importance of multidisciplinary and interprofessional collaboration, and present useful tips on using a shared decision-making approach in the management of HCC.
Overview of Hepatocellular Carcinoma (HCC; 10 min)
Current and Emerging Treatments of Unresectable HCC (20 min)
Multidisciplinary Care in HCC (10 min)
Patient Education and Shared Decision Making (15 min)
Q&A and Activity Conclusion (5 min)
This initiative is designed for oncologists, hepatologists, nurses, and other healthcare professionals who manage patients with liver cancer.
Josep M. Llovet, MD
|Richard S. Finn, MD|
Associate Professor of Medicine
Division of Hematology/Oncology
Geffen School of Medicine at UCLA
Los Angeles, CA
Riccardo Lencioni, MD
Lewis R. Roberts, MB ChB, PhD
Morris Sherman, PhD, MB, FRCPC
In support of improving patient care, AXIS Medical Education is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC) to provide continuing education for the healthcare team.
Credit Designation for Physicians
AXIS Medical Education designates this enduring activity for a maximum of 1.0 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Credit Designation for Nursing
AXIS Medical Education designates this continuing nursing education activity for 1.0 contact hours.
Learners are advised that accredited status does not imply endorsement by the provider or ANCC of any commercial products displayed in conjunction with an activity.
California Board of Registered Nursing
AXIS is approved by the California Board of Registered Nursing, Provider Number 16702, for 1.0 contact hour.
Iowa Board of Nursing
AXIS is Iowa Board of Nursing Approved Provider Number 371, for 1.0 contact hour.
Disclosure of Conflicts of Interest
AXIS Medical Education requires instructors, planners, managers, and other individuals and their spouse/life partner who are in a position to control the content of this activity to disclose any real or apparent conflict of interest they may have as related to the content of this activity. All identified conflicts of interest are thoroughly vetted by AXIS for fair balance, scientific objectivity of studies mentioned in the materials or used as the basis for content, and appropriateness of patient care recommendations.
AXIS will identify, review, and resolve all conflicts of interest that faculty, authors, activity directors, planners, managers, peer reviewers, or relevant staff disclose prior to an educational activity being delivered to learners. Disclosure of a relationship is not intended to suggest or condone bias in any presentation but is made to provide participants with information that might be of potential importance to their evaluation of a presentation. Disclosure information for speakers, authors, course directors, planners, peer reviewers, and/or relevant staff is provided with this activity.
The faculty reported the following financial relationships or relationships they or their spouse/life partner have with commercial interests related to the content of this continuing education activity:
|Name of Faculty or Presenter||Reported Financial Relationship|
|Josep M. Llovet, MD||Josep M Llovet, MD, reported a financial interest/relationship or affiliation in the form of: Advisor and Speaker, Bayer Pharmaceuticals Corporation, Blueprint Medicines, Blueprint Medicines, Bristol-Myers Squibb Company, Celsion Corporation, Eli Lilly and Company; Research grant, Bayer Pharmaceuticals Corporation, Blueprint Medicines; Bristol-Myers Squibb Company.|
|Richard S. Finn, MD||Richard S. Finn, MD, reported a financial interest/relationship or affiliation in the form of Consultant/Independent contractor fee paid to UCLA: Bayer Pharmaceuticals Corporation; Bristol-Myers Squibb Company; Novartis Pharmaceuticals Corporation; Pfizer, Inc.|
|Riccardo Lencioni, MD||Ricardo Lencioni, MD, reported a financial interest/relationship or affiliation in the form of Consultant, Bayer Healthcare, BTG, and Guerbet.|
|Lewis R. Roberts, MB ChB, PhD||Lewis R. Roberts, MB ChB, PhD, reported a financial interest/relationship or affiliation in the form of: Research grant, Gilead Sciences, and BTG.|
Morris Sherman, PhD, MB, FRCPC
|Morris Sherman, PhD, MB, FRCPC, reported a financial interest/relationship or affiliation in the form of: Speaker, Merck & Co., Inc., AbbVie, Bristol-Myers Squibb Company, Gilead; Received income in any amount from, Bayer HealthCare Pharmaceuticals., Celsion Corporation.|
The planners and managers reported the following financial relationships or relationships they or their spouse/life partner have with commercial interests related to the content of this continuing education activity:
The following AXIS planners and managers, Linda Gracie-King, MS, Ronald Viggiani, MD, Jocelyn Timko, and Marilyn Haas, PhD, RN, CNS, ANP-BC state that they or their spouse/life partner do not have any financial relationships or relationships to products or devices with any commercial interest of any amount during the past 12 months.
This activity has been supported by an educational grant from Bayer HealthCare Pharmaceuticals Inc.
There is no fee for this educational activity.
This activity is provided by:
- 1.00 ANCC
- 1.00 Attendance
- 1.00 AMA PRA Category 1 Credit™
At the conclusion of this activity, participants should be better able to:
- Summarize the efficacy and safety data for current and emerging therapies for unresectable hepatocellular carcinoma
- Implement a multidisciplinary approach to the treatment of hepatocellular carcinoma
- Use a shared decision-making approach with patients with hepatocellular carcinoma and their families to engage them in their care and potentially improve outcomes